London, February 24, 2010 (ots/PRNewswire) - First Quarter of 2010 has
shown some early signs of resurgence in life science IPO's that are
already underway or planned. BioTrinity, the UK's Premier
Biopartnering and Investment Conference, will be focusing on the
evidence for early success and the prospects for the remainder of the
year and into 2011 in a series of panel discussions aimed at
understanding the current marketplace, the way companies can maximise
their chances of a successful float and the support the City can give
to ensure success.

This is the 4th Annual BioTrinity Conference, which has evolved
into the UK's largest and arguably most successful Biopartnering and
Investment Conference. Because of its success the conference has
outgrown the Kassam Stadium, its home for the past two years and will
now take place at the Newbury Racecourse April 12-14th. A key driver
for the success of the conference has been its focused programme of
discussions and panel sessions tackling the current themes of most
interest to the biotechnology industry and more widely for the life
sciences industries in general.

The green shoots of recovery in the life sciences IPO market is a
key consideration for early venture investors as they look for
significant financial inflection points that will generate
shareholder value and equip their companies to take their products
and technologies through to commercialisation. A healthy IPO market
is a key element of this and therefore a focus of the BioTrinity
programme for this year.

Investment Banker James Steel, Director of Corporate Finance at
KBC Peel Hunt will lead the discussion helping life sciences
companies to understand the implications of the recent rise in IPO
activity on both sides of the Atlantic. His colleague Senior
Healthcare Analyst, Paul Cuddon, will provide additional input and
insights into the City's perception of life science companies
following the downturn and also give views on those areas of life
sciences which are more likely to be IPO candidates on the UK markets
over the coming months. .

These perspectives will be complimented by Ian Paling, CEO and
Exec Chairman of privately-held CellCoTec. As CEO of Corin Group Plc
Ian also guided that company through an IPO in 2002 and subsequently
grew it into a highly regarded publicly quoted orthopaedic company.
BioTrinity is also able to announce that Vernalis' CEO; Ian Garland
will join this panel discussion in the same week that Vernalis plc
announced plans to raise GBP30m on the public markets, These
perspectives will be provided by a leading venture capital house.

As part of it role in fostering partnership building, BioTrinity
features an exclusive pre-conference invitation-only five course wine
and tasting dinner at the Vineyard at Stockcross which is uniquely
designed to provide a convivial forum to encourage investors in the
sector to develop syndicates, exchange knowledge and cooperate on
future deals.

For further information, please contact:
Jon Rees
CEO, OBN
Tel: +44(0)1865-594642
Anna Dunphy
De Facto Communications
Tel: +44(0)20-7861-3838

ots Originaltext: Oxfordshire Bioscience Network (OBN)
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information, please contact: Jon Rees, CEO,
OBN, Tel:+44(0)1865-594642; Anna Dunphy, De Facto Communications,
Tel:+44(0)20-7861-3838.